December 23, 2002
NOTICE
Our file number: 02-122028-691
Withdrawal of Toxicological Evaluation Guidelines and
Re-issuance of ICH 1 Safety Guidances
The Health Canada Toxicological Evaluation guidances (revised
1996) are being withdrawn following an internal review by a Safety Expert
Working Group which concluded that they no longer reflected current toxicological
methodologies. Furthermore, the review revealed substantial areas of overlap
and inconsistency between these guidances and their more recently adopted
ICH counterparts.
The following Health Canada-adopted ICH Safety (Nonclinical) guidances,
previously available as part of the Toxicological Evaluation guidances,
are being re-issued as stand alone documents:
- S1A Need for Carcinogenicity Studies of Pharmaceuticals
- S2A Guidance on Specific Aspects of Regulatory Genotoxicity Tests
For Pharmaceuticals
- S3A Note for Guidance on Toxicokinetics: The Assessment of Systemic
Exposure in Toxicity Studies
- S3B Pharmacokinetics: Guidance for Repeated Dose Tissue Distribution
Studies
- S5A Detection of Toxicity to Reproduction for Medicinal Products
These ICH guidances have been developed by the appropriate ICH Expert
Working Group and have been subject to consultation by the regulatory
parties, in accordance with the ICH Process. The ICH Steering Committee
has endorsed the final draft and recommended its adoption by the regulatory
bodies of the European Union, Japan and USA.
In adopting these ICH guidances, Health Canada as observer to ICH, endorses
the principles and practices described therein. These documents should
be read in conjunction with this covering notice and with the relevant
sections of other applicable Health Canada guidance.
1 ICH - International Conference on Harmonization
of Technical Requirements for the Registration of Pharmaceuticals for
Human Use
These and other guidance documents are currently available on the Therapeutic
Products Directorate / Biologics and Genetic Therapies Directorate Website
(s) (http://www.hc-sc.gc.ca/hpfb-dgpsa/tpd-dpt/).
The availability of printed copies of guidance documents may be confirmed
by consulting the Guidelines and Publications Order Forms (available on
the TPD/BGTD Website) or by contacting the Publications Coordinator 2.
Should you have any questions regarding the content of the guidance,
please contact
Colette F. Strnad, B. Sc., Ph.D.
Title: Senior Scientific Advisor
Office of Science
Therapeutic Products Directorate
Holland Cross, Tower B, 2nd Floor,
A.L. 3102C3 1600 Scott Street
Ottawa, Ontario K1A 1B6
telephone: (613) 941-3693
fax: (613) 941-5035
email: colette_strnad@hc-sc.gc.ca
2 Tel: (613) 954-6466; E-mail: publications_coordinator@hc-sc.gc.ca
![redbar](/web/20061214002104im_/http://www.hc-sc.gc.ca/dhp-mps/prodpharma/images/redbar.gif)
S2A: Guidance on Specific Aspects Of Regulatory Genotoxicity
Tests For Pharmaceuticals
![redbar](/web/20061214002104im_/http://www.hc-sc.gc.ca/dhp-mps/prodpharma/images/redbar.gif)
Published by authority of the Minister of Health
![redbar](/web/20061214002104im_/http://www.hc-sc.gc.ca/dhp-mps/prodpharma/images/redbar.gif)
1996
Health Products and Food Branch Guidance Document
Our mission is to help the people of Canada
maintain and improve their health.
Health Canada |
HPFB's Mandate is to take an integrated approach to the management
of the risks and benefits to health related to health products and
food by:
- Minimizing health risk factors to Canadians while maximizing
the safety provided by the regulatory system for health products
and food; and,
- Promoting conditions that enable Canadians to make healthy choices
and providing information so that they can make informed decisions
about their health.
Health Products and Food Branch
|
© Minister of Public Works and Government Services Canada
1996
Available in Canada through
Health Canada -
Publications Brooke Claxton Building,
A.L. #0913A Tunney's Pasture
Ottawa, Ontario K1A 0K9
Tel: (613) 954-5995
Fax: (613) 941-5366
Également disponible en français sous le titre: Essais
réglementaires de génotoxicité des produits pharmaceutiques: Aspects particuliers
FOREWORD
This guidance has been developed by the appropriate ICH Expert Working
Group and has been subject to consultation by the regulatory parties,
in accordance with the ICH Process. The ICH Steering Committee has endorsed
the final draft and recommended its adoption by the regulatory bodies
of the European Union, Japan and USA.
In adopting this ICH guidance, Health Canada endorses the principles
and practices described therein. This document should be read in conjunction
with the accompanying notice and the relevant sections of other applicable
guidances.
Guidance documents are meant to provide assistance to industry and health
care professionals on how to comply with the policies and governing statutes
and regulations. They also serve to provide review and compliance guidance
to staff, thereby ensuring that mandates are implemented in a fair, consistent
and effective manner.
Guidance documents are administrative instruments not having force of
law and, as such, allow for flexibility in approach. Alternate approaches
to the principles and practices described in this document may be acceptable
provided they are supported by adequate scientific justification. Alternate
approaches should be discussed in advance with the relevant program area
to avoid the possible finding that applicable statutory or regulatory
requirements have not been met.
As a corollary to the above, it is equally important to note that Health
Canada reserves the right to request information or material, or define
conditions not specifically described in this guidance, in order to allow
the Department to adequately assess the safety, efficacy or quality of
a therapeutic product. Health Canada is committed to ensuring that such
requests are justifiable and that decisions are clearly documented.
TABLE OF CONTENTS
1. INTRODUCTION
2. SPECIFIC GUIDANCE AND
RECOMMENDATIONS
2.1. Specific Guidance for
in Vitro Tests
2.1.1. The Base Set of Strains Used in Bacterial Mutation
Assays
2.1.2. Definition of the Top Concentration for in Vitro
Tests
2.2. Specific Guidance for
in Vivo Tests
2.2.1. Acceptable Bone Marrow Tests for the Detection
of Clastogens in Vivo
2.2.2. Use of Male/female Rodents in Bone Marrow Micronucleus
Tests
2.3. Guidance on the Evaluation
of Test Results
2.3.1. Guidance on the Evaluation of in Vitro Test Results
2.3.2. Guidance on the Evaluation of in Vivo Test Results
3. NOTES
4. GLOSSARY
5. REFERENCES
1. INTRODUCTION
Guidelines for the testing of pharmaceuticals for genetic toxicity have
been established in the European Community (EEC, 1987) and Japan (Japanese
Ministry of Health and Welfare, 1989). FDA's centers for Drugs and Biologics
Evaluation and Research (CDER and CBER) currently consider the guidance
on genetic toxicity testing provided by the FDA Center for Food Safety
and Applied Nutrition (Federal Register notice, March 29, 1993)
to be applicable to pharmaceuticals.
The following notes for guidance should be applied in conjunction with
existing guidelines in the USA, the European Community and Japan. The
recommendations below are derived from considerations of historical information
held within the international pharmaceutical industry, the three regulatory
bodies and the scientific literature. Where relevant the recommendations
from the latest review of OECD Guidelines (OECD, 1994) and the 1993 International
Workshop on Standardisation of Genotoxicity Test Procedures (Mutation
Research No. 312(3), 1994) have been considered.
![Top of Page](/web/20061214002104im_/http://www.hc-sc.gc.ca/images/dhp-mps/arrow_up.gif)
2. SPECIFIC GUIDANCE AND RECOMMENDATIONS
2.1. Specific Guidance for in Vitro Tests
2.1.1. The Base Set of Strains Used in Bacterial Mutation Assays
Current guidances for the detection of bacterial mutagens employ several
strains to detect base substitution and frameshift point mutations. The
Salmonella typhimurium strains mentioned in guidelines (normally
TA 1535, TA1537, TA98 and TA100) will detect such changes at G-C (guanine-cytosine)
sites within target histidine genes. It is clear from the literature that
some metagenic carcinogens also modify A-T (adeninethymine) base pairs.
Therefore the standard set of strains used in bacterial mutation assays
should include strains that will detect point mutations at A-T sites,
such as Salmonella typhimurium TA102, which detects such mutations
within multiple copies of hisG genes or Escherichia coli
WP2 uvrA, which detects these mutations in the trpE gene
or the same strain possessing the plasmid (pKM101), which carries mucAB
genes that enhance error prone repair (see note 1). In conclusion, the
following base set of bacterial strains should be used for routine testing:
the strains cited below are all Salmonella typhimurium isolates,
unless specified otherwise.
In order to detect cross-linking agents it may be preferable to select
Salmonella typhimurium TA102 or to add a repair proficient Escherichia
coli strain, such as WP2 pKM101. It is noted that such compounds are
detected in assays that measure chromosome damage.
1. TA98; 2. TA100; 3. TA1535; 4. TA1537 or TA97 or TA97a (see note 2);
5. TA102 or Escherichia coli WP2 uvrA or Escherichia
coli WP2 uvrA (pKM101).
2.1.2. Definition of the Top Concentration for in Vitro Tests
2.1.2.1. High Concentration for Non-toxic Compounds
For freely soluble, non-toxic compounds, the desired upper treatment
levels are 5mg/plate for bacteria and 5mg/ml or 10mM (whichever is the
lower) for mammalian cells.
2.1.2.2. Desired Level of Cytotoxicity
Some genotoxic carcinogens are not detectable in in vitro genotoxicity
assays unless the concentrations tested induce some degree of cytotoxicity.
It is also apparent that excessive toxicity often does not allow a proper
evaluation of the relevant genetic endpoint. Indeed at very low survival
levels in mammalian cells, mechanisms other than direct genotoxicity per
se can lead to "positive" results that are related to cytotoxicity and
not genotoxicity (e.g. events associated with apoptosis, endonuclease
release from lysosomes, etc.). Such events are likely to occur once a
certain concentration threshold is reached for a toxic compound.
To balance these conflicting considerations the following levels of cytotoxicity
are currently acceptable for in vitro bacterial and mammalian cell
tests (concentrations should not exceed the levels specified in 2.1.2.1.):
- In the bacterial reverse mutation test, the highest concentration
of test compound is desired to show evidence of significant toxicity.
Toxicity may be detected by a reduction in the number of revertants,
a clearing or diminution of the background lawn.
- The desired level of toxicity for in vitro cytogenetic tests
using cell lines should be greater than 50% reduction in cell number
or culture confluency. For lymphocyte cultures, an inhibition of mitotic
index by greater than 50% is considered sufficient.
- In mammalian cell mutation tests ideally the highest concentration
should produce at least 80% toxicity (no more than 20% survival). Toxicity
can be measured either by assessment of cloning efficiency (e.g. immediately
after treatment), or by calculation of relative total growth, i.e. the
product of relative suspension growth during the expression period and
relative plating efficiency at the time of mutant selection. Caution
is due with positive results obtained at levels of survival lower than
10%.
2.1.2.3. Testing of Poorly Soluble Compounds
There is some evidence that dose-related genotoxic activity can be detected
when testing certain compounds in the isolable range in both bacterial
and mammalian cell genotoxicity tests. This is generally associated with
dose-related toxicity (see note 3). It is possible that solubilization
of a precipitate is enhanced by serum in the culture medium or in the
presence of S9-mix constituents. It is also probably that cell membrane
lipid can facilitate absorption of lipophilic compounds into cells. In
addition some types of mammalian cells have endocytic activity (e.g. Chinese
hamster V79; CHO and CHL cells) and can ingest solid particles which may
subsequently disperse into the cytoplasm. An insoluble compound may also
contain soluble genotoxic impurities. It should also be noted that a number
of insoluble pharmaceuticals are administered to humans as suspensions
or as particulate materials.
On the other hand heavy precipitates can interfere with scoring the desired
parameter and render control of exposure very difficult (e.g. where a
centrifugation step(s) is included in a protocol to remove cells from
exposure media) (see note 4); or render the test compound unavailable
to enter cells and interact with DNA.
The following strategy is recommended for testing relatively insoluble
compounds. The recommendation below refers to the test article in the
culture medium.
If no cytotoxicity is observed then the lowest precipitating concentration
should be used as the top concentration but not exceeding 5mg/plate for
bacterial tests and 5mg/ml or 10mM for mammalian cell tests. If dose-related
cytotoxicity or mutagenicity is noted, irrespective of solubility, then
the top concentration should be based on toxicity as described above.
This may require the testing of more than one precipitating concentration
(not to exceed the above stated levels). It is recognised that the desired
levels of cytotoxicity may not be achievable if the extent of precipitation
interferes with the scoring of the test. In all cases precipitation should
be evaluated at the beginning and at the end of the treatment period using
the naked eye.
![Top of Page](/web/20061214002104im_/http://www.hc-sc.gc.ca/images/dhp-mps/arrow_up.gif)
2.2. Specific Guidance for in Vivo Tests
2.2.1. Acceptable Bone Marrow Tests for the Detection of Clastogens
in Vivo
Tests measuring chromosomal aberrations in nucleated bone marrow cells
in rodents can detect a wide spectrum of changes in chromosomal integrity.
These changes almost all result from breakage of one or more chromatids
as the initial event. Breakage of chromatids or chromosomes can result
in micronucleus formation if an acentric fragment is produced; therefore
assays detecting either chromosomal aberrations or micronuclei are acceptable
for detecting clastogens (see note 5). Micronuclei can also result from
lagging of one or more whole chromosome(s) at anaphase and thus Micronucleus
tests have the potential to detect some aneuploidy inducers (see note
6).
In conclusion either the analysis of chromosomal aberrations in bone
marrow cells or the measurement of micronucleated polychromatic erythrocytes
in bone marrow cells in vivo is acceptable for the detection of clastogens.
The measurement of micronucleated immature (e.g. polychromatic) erythrocytes
in peripheral blood is an acceptable alternative in the mouse, or in any
other species in which the inability of the spleen to remove micronucleated
erythrocytes has been demonstrated, or which has shown an adequate sensitivity
to detect clastogens/aneuploidy inducers in peripheral blood (see note
7).
2.2.2. Use of Male/female Rodents in Bone Marrow Micronucleus Tests
Extensive studies of the activity of known clastogens in the mouse bone
marrow micronucleus test have shown that in general male mice are more
sensitive than female mice for micronucleus induction (see note 8). Quantitative
differences in micronucleus induction have been identified between the
sexes, but no qualitative differences have been described. Where marked
quantitative differences exist, there is invariably a difference in toxicity
between the sexes. If there is a clear qualitative difference in metabolites
between male and female rodents, then both sexes should be used. Similar
principles can be applied for other established in vivo tests (see note
9). Both rats and mice are deemed acceptable for use in the bone marrow
micronucleus test (see note 10).
In summary, unless there are obvious differences in toxicity or metabolism
between male and female rodents, then males alone are sufficient for use
in bone marrow micronucleus tests. If gender-specific drugs are to be
tested, then normally animals of the corresponding sex should be used.
![Top of Page](/web/20061214002104im_/http://www.hc-sc.gc.ca/images/dhp-mps/arrow_up.gif)
2.3. Guidance on the Evaluation of Test Results
Comparative trials have shown conclusively that each in vitro test system
generates both false negative and false positive results in relation to
predicting rodent carcinogenicity. Genotoxicity test batteries (of in vitro and in vivo tests) detect carcinogens that are thought to act primarily
via a mechanism involving direct genetic damage, such as the majority
of known human carcinogens. Therefore, these batteries may not detect
non-genotoxic carcinogens. Experimental conditions, such as the limited
capability of the in vitro metabolic activation systems, can also lead
to false negative results in in vitro tests. The test battery approach
is designed to reduce the risk of false negative results for compounds
with genotoxic potential, while a positive result in any assay for genotoxicity
does not necessarily mean that the test compound poses a genotoxic/carcinogenic
hazard to humans.
2.3.1. Guidance on the Evaluation of in vitro Test Results
2.3.1.1. in vitro Positive Results
The scientific literature gives a number of conditions which may lead
to a positive in vitro result of questionable relevance. Therefore, any
in vitro positive test result should be evaluated for its biological relevance
taking into account the following considerations (this is not exhaustive,
but is given as an aid to decision-making):
- Is the increase in response over the negative or solvent control
background regarded as a meaningful genotoxic effect for the cells?
- Is the response concentration-related?
- For weak/equivocal responses, is the effect reproducible
- Is the positive result a consequence of an in vitro specific metabolic
activation pathway/in vitro specific active metabolite (see also note
12)?
- Can the effect be attributed to extreme culture conditions that do
not occur in in vivo situations, e.g. extremes of pH; osmolality; heavy
precipitates especially in cell suspensions (see note 4)?
- For mammalian cells, is the effect only seen at extremely low survival
levels (see section 2.1.2.2. for acceptable levels of toxicity)?
- Is the positive result attributable to a contaminant (this may be
the case the compound shows no structural alerts or is weakly mutagenic
or mutagenic only at very high concentrations)?
- Do the results obtained for a given genotoxic endpoint conform to
that for other compounds of the same chemical class?
2.3.1.2. in vitro Negative Results
For in vitro negative results special attention should be paid to the
following considerations (the examples given are not exhaustive, but are
given as an aid to decision-making): Does the structure or known metabolism
of the compound indicate that standard techniques for in vitro metabolic
activation (e.g. rodent liver S9) may be inadequate? Does the structure
or known reactivity of the compound indicate that the use of other test
methods/systems may be appropriate?
2.3.2. Guidance on the Evaluation of in Vivo Test Results
In vivo tests, by their nature, have the advantage of taking into account
absorption, distribution and excretion, which are not factors in in vitro
tests, but are relevant to human use. In addition metabolism is likely
to be more relevant in vivo compared to the systems normally used in vitro.
There are a few validated in vivo models accepted for assessment of genotoxicity.
These include the bone marrow or peripheral blood cytogenetic assays.
If a compound has been tested in vitro with negative results, it is usually
sufficient to carry out a single in vivo cytogenetics assay.
For a compound that induces a biologically relevant positive result in
one or more in vitro tests (see section 2.3.1.1.), a further in vivo test
in addition to the in vivo cytogenetic assay, using a tissue other than
the bone marrow/peripheral blood, can provide further useful information.
The target cells exposed in vivo and possibly the genetic endpoint measured
in vitro guide the choice of this additional in vivo test. However, there
is no validated, widely used in vivo system which measures gene mutation.
In vivo gene mutation assays using endogenous genes or transgenes in several
tissues of the rat and mouse are at various stages of development. Until
such tests for mutation become accepted, results from other in vivo tests
for genotoxicity in tissues other than the bone marrow can provide valuable
additional data but the assay of choice should be scientifically justified
(see note 11).
If in vivo and in vitro test results do not agree, then the differences
should be considered / explained on a case-by-case basis (see sections
2.3.1.1. and 2.3.2.1., and note 12).
In conclusion, the assessment of the genotoxic potential of a compound
should take into account the totality of the findings and acknowledge
the intrinsic values and limitations of both in vitro and in vivo tests.
2.3.2.1. Principles for Demonstration of Target Tissue Exposure for
Negative in Vivo Test Results
In vivo tests have an important role in genotoxicity test strategies.
The significance of in vivo results in genotoxicity test strategies is
directly related to the demonstration of adequate exposure of the target
tissue to the test compound. This is especially true for negative in vivo
test results and when in vitro test(s) have shown convincing evidence
of genotoxicity. Although a dose sufficient to elicit a biological response
(e.g. toxicity) in the tissue in question is preferable, such a dose could
prove to be unattainable since dose-limiting toxicity can occur in a tissue
other than the target tissue of interest. In such cases, toxicokinetic
data can be used to provide evidence of bioavailability. If adequate exposure
cannot be achieved e.g. with compounds showing very poor target tissue
availability, extensive protein binding etc., conventional in vivo genotoxicity
tests may have little value.
The following recommendations apply to bone marrow cytogenetic assays,
as examples; if other target tissues are used, similar principles should
be applied.
For compounds showing positive results in any of the in vitro tests employed
demonstration of in vivo exposure should be made by any of the following
measurements:
- By obtaining a significant change in the proportion of immature erythrocytes
among total erythrocytes in the bone marrow, at the doses and sampling
times used in the micronucleus test or by measuring a significant reduction
in mitotic index for the chromosomal aberration assay.
- Evidence of bioavailability of drug-related material either by measuring
blood or plasma levels (see note 13).
- By direct measurement of drug-related material in bone marrow.
- By autoradiographic assessment of tissue exposure.
For methods ii) to iv), assessments should be made preferentially at
the top dose or other relevant doses using the same species/strain and
dosing route used in the bone marrow assay.
If in vitro tests do not show genotoxic potential, in vivo (systemic)
exposure should be demonstrated and can be achieved by any of the methods
above, but can also be inferred from the results of standard absorption,
distribution, metabolism and excretion (ADME) studies in rodents.
2.3.2.2. Detection of Germ Cell Mutagens
With respect to the detection of germ cell mutagens, results of comparative
studies have shown that, in a qualitative sense, most germ cell mutagens
are likely to be detected as such in somatic cell tests and negative results
of in vivo somatic cell genotoxicity tests generally indicate the absence
of germ cell effects (see note 14).
![Top of Page](/web/20061214002104im_/http://www.hc-sc.gc.ca/images/dhp-mps/arrow_up.gif)
3. NOTES
- Relevant examples of genotoxic carcinogens that are detected if bacterial
strains with A-T target mutations are included in the base set can be
found in the literature (e.g. Levin et al., 1983; Wilcox et al., 1990).
Analysis of the database held by the Japanese Ministry of Labour on
5526 compounds (and supported by smaller databases held by various pharmaceutical
companies), has shown that approximately 7.5% of the bacterial mutagens
identified are detected by E. coli WP2 uvrA, but not by
the standard set of four Salmonella strains. Although animal carcinogenicity
date are not available on these compounds, it is likely that such compounds
would carry the same carcinogenic potential as mutagens inducing changes
in the standard set of Salmonella strains.
- TA1537, TA97 and TA97a all contain cytosine runs at the mutation
sensitive site within the relevant target histidine loci and show similar
sensitivity to frameshift mutagens that induce deletion of bases in
these frameshift hotspots. There was consensus agreement at the International
Workshop on Standardisation of Genotoxicity Procedures, Melbourne, 1993,
(Gatehouse et al., 1994) that all three strains could be used interchangeably.
- Laboratories in Japan carrying out genotoxicity tests have much experience
in testing precipitates and have identified examples of substances that
are clearly genotoxic only in the precipitating range of concentrations.
These compounds include polymers and mixtures of compounds; some polycyclic
hydrocarbons; some phenylene diamines; heptachlor etc.. Collaborative
studies with some of these compounds have shown that they may be detectable
in the soluble range, however it does seem clear that genotoxic activity
increases well into the insoluble range. A discussion of these factors
is given in the report of the in vitro sub group of the International
Workshop on Standardisation of Genotoxicity Procedures, Melbourne, 1993
(Kirkland, 1994).
- Testing compounds in the precipitating range is problematical with
respect to defining the exposure periods for assays where the cells
grow in suspension. After the defined exposure period, the cells are
normally pelleted by centrifugation and are then resuspended in fresh
medium without the test compound. If a precipitate is present, the compound
will be carried through to the later stages of the assay making control
of exposure impossible. If such cells are used e.g. human peripheral
lymphocytes or mouse lymphoma cells, it is reasonable to use the lowest
precipitating concentration as the highest tested.
- As the mechanisms of micronucleus formation are related to those
inducing chromosomal aberrations (e.g. Hayashi et al., 1984 and 1994;
Hayashi, 1994), both micronuclei and chromosomal aberrations can be
accepted as assay systems to screen for clastogenicity induced by test
compounds. Comparisons of data where both the mouse micronucleus test
and rat bone marrow metaphase analysis have been carried out on the
same compounds have shown impressive correlation both qualitatively
i.e. detecting clastogenicity and quantitatively i.e. determination
of the lowest clastogenic dose. Even closer correlations can be expected
where the data are generated in the same species.
- Although micronuclei can arise from lagging whole chromosomes following
interaction of a compound with the spindle apparatus, the micronucleus
test may not detect all aneuploidy inducers. Specific aneuploidy assays
may become available in the near future. One approach is the evolving
rapid and sensitive technique for identifying individual (rodent) chromosomes
in interphase nuclei, e.g. via fluorescence in situ hybridisation (FISH).
- The peripheral blood micronucleus test in the mouse using acridine
orange supravital staining, was originally introduced by Hayashi et
al. (1990). The test has been the subject of a major collaborative study
by the Japanese Collaborative Study Group for the Micronucleus Test
(Mutation Research, 278, 1992, Nos. 2/3). The tests were carried out
in CD-1 mice using 23 test substances of various modes of action. Peripheral
blood sampled from the same animal was examined 0, 24, 48 und 72 hours
(or longer) after treatment. As a rule one chemical was studied by two
different laboratories (46 laboratories took part). All chemicals were
detected as inducers of micronuclei. There were quantitative differences
between laboratories, but no qualitative differences. Most chemicals
gave the greatest response 48 hours after treatment. Thus the results
suggest that the peripheral blood micronucleus assay using acridine
orange supravital staining can generate reproducible and reliable data
to evaluate the clastogenicity of chemicals. Based on these data, the
International Workshop on Standardisation of Genotoxicity Procedures,
Melbourne, 1993 concluded that this assay is equivalent in accuracy
to the bone marrow micronucleus assay (Hayashi et al., 1994). The application
of the peripheral blood micronucleus assay to rats is under validation
by the Japanese Collaborative Study Group for the Micronucleus Test.
- A detailed collaborative study was carried out indicating that in
general male mice were more sensitive than female mice for micronucleus
induction, but where differences were seen they were only quantitative
and not qualitative (The Collaborative Study Group for the Micronucleus
Test, 1986). This analysis has been extended by the group considering
the micronucleus test at the International Workshop on Standardisation
of Genotoxicity Procedures, Melbourne, 1993 and having analysed data
on 53 in vivo clastogens (and 48 non-clastogens), the same conclusions
were drawn (Hayashi et al., 1994).
- As the induction of micronuclei and chromosomal aberrations are related,
it is reasonable to assume that the same conditions can be applied when
using male animals in bone marrow chromosomal aberration assays. The
peripheral blood micronucleus test has been validated only in male rodents
(The Collaborative Study Group for the Micronucleus Test, 1992) as has
the ex vivo UDS test (Kennely et al., 1993; Madle et al., 1994).
- Both the rat and mouse are suitable species for use in the micronucleus
test with bone marrow. However data are accumulating to show that some
species specific carcinogens are species specific genotoxins (e.g. Albanese
et al., 1988). When more data have accumulated there may be a case for
carrying out micronucleus tests in both the rat and the mouse.
- Apart from the cytogenetic assays in bone marrow cells, a large database
for in vivo assays exists for the liver unscheduled DNA synthesis (UDS)
assay (Madle et al., 1994). A review of the literature shows that a
combination of the liver UDS test and the bone marrow micronucleus test
will detect most genotoxic carcinogens with few false positive results
(Tweats, 1994). False negative results with this combination of assays
have been generated for some unstable genotoxic compounds and certain
aromatic amines which are problematical for most existing in vivo screens
(Tweats, 1994) Therefore, further in vivo testing should not be restricted
to liver UDS tests as other assays may be more appropriate (e.g. 32p
post-labeling; DNA strand-breakage assays etc.), depending on the compound
in question. It is important to recognize that for these in vivo endpoints
their relationship to mutation is not precisely known.
- Examples to consider regarding the difference between in vitro
and in vivo test results have been described in the literature.
They include: (i) an active metabolite produced in vitro may
not be produced in vivo, (ii) an active metabolite may be rapidly
detoxified in vivo but not in vitro, (iii) rapid and efficient
excretion of a compound may occur in vivo, etc. Examples such
as these have been described (e.g. Ashby, 1983).
- The bone marrow is a well perfused tissue and it can be deduced therefore
that levels of drug-related materials in blood or plasma will be similar
to those observed in bone marrow. This is borne out by direct comparisons
of drug levels in the two compartments for a large series of different
pharmaceuticals (Probst, 1994). Although drug levels are not always
the same, there is sufficient correlation for measurements in blood
or plasma to be adequate for validating bone marrow exposure.
- There may be specific types of mutagens, e.g. aneuploidy inducers,
which act preferentially during meiotic gametogenesis stages. There
is no conclusive experimental evidence for the existence of such substances
to date.
![Top of Page](/web/20061214002104im_/http://www.hc-sc.gc.ca/images/dhp-mps/arrow_up.gif)
4. GLOSSARY
aneuploidy: numerical deviation of the modal number of chromosomes
in a cell or organism.
base substitution: the substitution of one or more base(s) for
another in the nucleotide sequence. This may lead to an altered protein.
cell proliferation: the ability of cells to divide and to form
daughter cells.
clastogen: an agent that produces structural changes of chromosomes,
usually detectable by light microscopy.
cloning efficiency: the efficiency of single cells to form clones.
Usually measured after seeding low numbers of cells in a suitable environment.
culture confluency: a quantification of the cell density in a
culture (cell proliferation is usual, inhibited at high degrees of confluency).
frameshift mutation: a mutation (change in the genetic code)
in which one base or two adjacent bases are added (inserted) or deleted
to the nucleotide sequence of a gene. This may lead to an altered or truncated
protein.
gene mutation: a detectable permanent change within a single
gene or its regulating sequences. The changes may be point mutations,
insertions, deletions.
genetic endpoint: the precise type or type class of genetic change
investigated (e.g. gene mutations, chromosomal aberrations. DNA-repair,
DNA-adduct formation, etc.)
genetic toxicity, genotoxicity: a broad term that refers to any
deleterious change in the genetic material regardless of the mechanism
by which the change is induced.
micronucleus: particle in a cell that contains microscopically
detectable nuclear DNA; it might contain a whole chromosome(s) or a broken
centric or acentric part(s) of chromosome(s). The size of a micronucleus
is usually defined as being less than 1/5 but more than 1/20 of the main
nucleus.
mitotic index: percentage of cells in the different stages of
mitosis amongst the cells not in mitosis (interphase) in a preparation
(slide).
plasmid: genetic element additional to the normal bacterial genome.
A plasmid might be inserted into the host chromosome or form an extra
chromosomal element.
point mutations: changes in the genetic code, usually confined
to a single DNA base pair.
polychromatic erythrocyte: an immature erythrocyte in an intermediate
stage of development that still contains ribosomes and, as such, can be
distinguished from mature normochromatic erythrocytes (lacking ribosomes)
by stains selective for ribosomes.
survival (in the context of mutagenicity testing): proportion
of cells in a living stage among dead cells, usually determined by staining
and colony counting methods after a certain treatment interval.
unscheduled DNA synthesis (UDS): DNA synthesis that occurs at
some stage in the cell cycle other than S-phase in response to DNA damage.
It is usually associated with DNA excision repair.
![Top of Page](/web/20061214002104im_/http://www.hc-sc.gc.ca/images/dhp-mps/arrow_up.gif)
5. REFERENCES
Albanese, R., Mirkova, E., Gatehouse, D. and Ashby, J. (1988) Species-specific
response to the rodent carcinogens. 1,2-dimethylhydrazine and 1,2-dibromochloropropane
in rodent bone marrow micronucleus assays, Mutagenesis, 3, 35-38
Ashby, J. (1983) The unique role of rodents in the detection of possible
human carcinogens and mutagens. Mutat. Res. 115, 177-213
EEC (1987) Notes for Guidance for the Testing of Medicinal Products for
their Mutagenic Potential. Official Journal Eur. Comm. L73
Gatehouse, D., Haworth, S., Cebula, T, Gocke, E., Kier, L., Matsushima,
T, Melcion, C., Nohmi T, Ohta, T, Venitt S. and Zeiger, E. (1994) Report
from the working group on bacterial mutation assays: International workshop
on standardisation of genotoxicity test procedures. Mutat. Res. 312, 217-233
Hayashi, M., Sofuni, T and Ishidate, M. Jr. (1984) Kinetics of micronucleus
formation in relation to chromosomal aberration in mouse bone marrow.
Mutat. Res. 127, 129-137
Hayashi, M., Morita, T, Kodama, Y., Sofuni, T and Ishidate, M. Jr. (1990)
The micronucleus assay with mouse peripheral blood reticulocytes using
acridine orange-coated slides. Mutat. Res. 245, 245- 249
Hayasi, M., Tice, R.R., MacGregor, J.T, Anderson, D., Blakey, D.K., Kirsch-Volders,
M., Oleson, F.B. Jr., Pacchierotti, F., Romagna, F., Shimada, H., Sutou,
S. and Vannier, B. (1994) In vivo rodent erythrocyte micronucleus assay.
Mutat. Res. 312 (3), 293-304
Hayasi, M. (1994) Acceptability of in vivo M.N. and C.A. tests. In: P.F.
D'Arcy and D.W.G. Harron (eds.) Proceedings of the Second International
Conference on Harmonisation (ICH 2), Greystoke Books Ltd., N. Ireland,
pp 232-237
Japanese Ministry of Health and Welfare (1989) Guidelines for toxicity
studies of drugs
Kenelly, J.C., Waters, R., Ashby, J., Lefevre, P.A., Burlinson, B., Benford,
D.J., Dean S.W. and Mitchell I. deG (1993) In vivo rat liver UDS assay.
In: Supplementary Mutagenicity Tests, UKEMS Recommended Procedures, ed
Kirkland D.J. and Fox M., Cambridge University Press, pp 52-77
Kirkland, D. (1994) Report of the in vitro sub-group. International workshop
on standardisation of Genotoxicity Test Procedures. Mutat. Res. 312, 211-215
Levin, D.E., Hollstein, M., Christman, M.F., Schwiers, E.A. and Ames,
B.N. (1982) A new Salmonella tester strain (TA102) with A-T base pairs
at the site of mutation detects oxidative mutagens. Proc. Nat. Acad. Sci.
USA 79, 7445-7449
Madle, S., Dean, S.W., Andrae, U., Brambilla, G., Burlinson, B., Doolittle,
D.J., Furihata, C., Hertner, T, McQueen, C.A. and Mori, H. (1994) Recommendations
for the performance of UDS tests in vitro and in vivo. Mutat. Res. 312,
263-285
OECD Guidelines for Genetic Toxicology (1983, 1984, 1986) Published by
OECD, Paris; latest revisions discussed at ad hoc expert committee meeting,
Rome, September 1994
Probst, G. (1994) Validation of target tissue exposure for in vivo tests,
In: P.F. D'Arcy and D.W.G. Harron (eds.) Proceedings of the Second International
Conference on Harmonisation (ICH 2), Greystoke Books Ltd., N. Ireland,
pp 249-252
The Collaborative Study Group for the Micronucleus Test, CSGMT (1986)
Sex difference in the micronucleus test. Mutat. Res. 172, 151-163
The Collaborative Study Group for the Micronucleus Test, CSGMT (1992)
Micronucleus test with mouse peripheral blood erythrocytes by acridine
orange supravital staining: The summary report of the 5th collaborative
study by CSGMT/JEMS: MMS. Mutat. Res. 278, 83-98
Tweats, D.J. (1994) Follow-up of in vitro positive results. In: P.F.
D'Arcy and D.W.G. Harron (eds.) Proceedings of the Second International
Conference on Harmonisation (ICH 2), Greystoke Books Ltd., N. Ireland,
pp 240-244
Wilcox, P., Naidoo, A., Wedd, D.J. and Gatehouse, D.G. (1990) Comparison
of Salmonella typhimurium TA102 with Escherichia coli WP2 tester strains.
Mutagenesis 5, 285-291
|